Anticoagulant fusion protein anchored to cell membrane
AssigneeImperial College Innovative Limited
InventorsKristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
Life of this patent
Estimating the term…
Loading patent…
AssigneeImperial College Innovative Limited
InventorsKristian Riesbeck, Anthony Dorling, Andrew John Timothy George, Robert Ian Lechler
Estimating the term…
The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).
A protein comprising (i) a region with anticoagulant activity, (ii) a transmembrane sequence from a membrane protein that can anchor said protein to a cell membrane;
Dependencies are inferred from the claim text.